27,549 Shares in DexCom, Inc. $DXCM Acquired by Quantitative Investment Management LLC

Quantitative Investment Management LLC purchased a new position in shares of DexCom, Inc. (NASDAQ:DXCM) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 27,549 shares of the medical device company’s stock, valued at approximately $1,855,000.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Norges Bank purchased a new stake in shares of DexCom in the 4th quarter valued at $483,356,000. AQR Capital Management LLC increased its stake in shares of DexCom by 597.8% in the fourth quarter. AQR Capital Management LLC now owns 3,102,789 shares of the medical device company’s stock worth $205,932,000 after acquiring an additional 2,658,158 shares during the period. Legal & General Group Plc purchased a new position in shares of DexCom during the second quarter worth $173,237,000. Deutsche Bank AG acquired a new position in DexCom during the second quarter valued at $164,035,000. Finally, Employees Provident Fund Board acquired a new position in DexCom during the fourth quarter valued at $145,352,000. 97.75% of the stock is currently owned by institutional investors and hedge funds.

DexCom Stock Performance

NASDAQ DXCM opened at $91.06 on Tuesday. The stock has a market capitalization of $34.36 billion, a price-to-earnings ratio of 35.99, a PEG ratio of 1.53 and a beta of 1.41. The stock has a 50-day moving average of $79.64 and a 200 day moving average of $71.77. The company has a current ratio of 1.73, a quick ratio of 1.43 and a debt-to-equity ratio of 0.47. DexCom, Inc. has a twelve month low of $54.11 and a twelve month high of $92.59.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, July 30th. The medical device company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.61 by $0.09. The company had revenue of $1.31 billion for the quarter, compared to analyst estimates of $1.29 billion. DexCom had a return on equity of 35.94% and a net margin of 20.12%.DexCom’s quarterly revenue was up 13.1% compared to the same quarter last year. During the same period last year, the company earned $0.48 earnings per share. Sell-side analysts anticipate that DexCom, Inc. will post 2.64 EPS for the current fiscal year.

Insider Transactions at DexCom

In other DexCom news, EVP Michael Jon Brown sold 1,700 shares of the stock in a transaction on Monday, June 15th. The shares were sold at an average price of $75.55, for a total transaction of $128,435.00. Following the transaction, the executive vice president directly owned 106,353 shares of the company’s stock, valued at $8,034,969.15. This trade represents a 1.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin R. Sayer sold 26,756 shares of the business’s stock in a transaction dated Monday, July 20th. The stock was sold at an average price of $76.32, for a total transaction of $2,042,017.92. Following the sale, the insider directly owned 328,970 shares of the company’s stock, valued at $25,106,990.40. This represents a 7.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 75,600 shares of company stock worth $5,673,342 in the last ninety days. Company insiders own 0.28% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. Wells Fargo & Company increased their price target on DexCom from $85.00 to $90.00 and gave the stock an “overweight” rating in a research report on Friday, July 31st. Barclays reaffirmed an “underweight” rating and set a $64.00 target price (down from $67.00) on shares of DexCom in a report on Monday, May 18th. Argus upped their price objective on DexCom from $86.00 to $96.00 and gave the stock a “buy” rating in a research report on Tuesday, August 4th. Bank of America cut their target price on shares of DexCom from $100.00 to $80.00 and set a “buy” rating for the company in a report on Monday, May 18th. Finally, TD Cowen reissued a “buy” rating on shares of DexCom in a report on Friday, July 31st. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $88.71.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.